Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PNU-103017 is an inhibitor of HIV protease.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,970.00 | |
50 mg | 8-10 weeks | $ 2,580.00 | |
100 mg | 8-10 weeks | $ 3,400.00 |
Description | PNU-103017 is an inhibitor of HIV protease. |
In vivo | PNU-103017 is a racemic mixture of two enantiomers, designated PNU-103264 (R-) and PNU-103265 (S-). PNU-103017 is a selective HIV aspartyl protease inhibitor under evaluation as a potential oral treatment of Acquired Immunodeficiency Diseases. The Cmax (P≤0.0349), Cmin (P≤0.0168), and Cav (P≤0.0118) are significantly higher for the (R)- than the (S)-enantiomer, displaying enantioselective pharmacokinetics of PNU-103017 in the dog[1]. |
Molecular Weight | 504.6 |
Formula | C28H28N2O5S |
CAS No. | 166335-18-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PNU-103017 166335-18-8 Microbiology/Virology Proteases/Proteasome HIV Protease PNU103017 PNU 103017 inhibitor inhibit